Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Executive Summary

With the first few cell and gene therapies launched in the US, the challenge of pricing and reimbursement – and the opportunity to set the standards in this area – was a repeated theme at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa.

Advertisement

Related Content

Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
Another CAR-T First: Yescarta Wins Lymphoma Funding In England
Kymriah: England Becomes First In Europe To Say Yes To CAR-T
Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain
CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel